Literature DB >> 2690972

Megestrol acetate versus aminoglutethimide for metastatic breast cancer.

S Lundgren1, S Gundersen, R Klepp, P E Lønning, E Lund, S Kvinnsland.   

Abstract

In this prospective, randomized study the clinical response and toxicity of megestrol acetate (MA) and aminoglutethimide (AG) as second-line treatment in patients with metastatic breast cancer was compared. 176 patients were included, and 150 received treatment greater than 8 weeks and are evaluable for treatment response. The two groups did not differ with regard to prognostic factors. Response rate for the AG and MA groups were 34% and 31% respectively, with duration of response of 13.1 and 13.0 months. Stable disease was obtained in 33% and 35% respectively. No difference was observed in survival. Side effects occurred more frequently in the AG group (42%) than in the MA group (18%).

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2690972     DOI： 10.1007/bf01810736

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  15 in total

1.  [Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study].

Authors:  H E Wander; U R Kleeberg; E Gärtner; J Hartlapp; A Scherpe; E Bönisch; G A Nagel
Journal:  Onkologie       Date:  1987-04

2.  Occupied and unoccupied nuclear oestradiol receptor in human breast tumours: relation to oestradiol and progesterone cytosol receptors.

Authors:  T Thorsen
Journal:  J Steroid Biochem       Date:  1979-06       Impact factor: 4.292

3.  Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.

Authors:  L R Morgan
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

4.  A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer.

Authors:  R B Buchanan; R W Blamey; K R Durrant; A Howell; A G Paterson; P E Preece; D C Smith; C J Williams; R G Wilson
Journal:  J Clin Oncol       Date:  1986-09       Impact factor: 44.544

5.  Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.

Authors:  R J Santen; T J Worgul; A Lipton; H Harvey; A Boucher; E Samojlik; S A Wells
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

6.  Treatment of breast carcinoma with aminoglutethimide.

Authors:  S Kvinnsland; P E Lønning; O Dahl
Journal:  Acta Radiol Oncol       Date:  1984

7.  Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.

Authors:  I E Smith; A L Harris; M Morgan; H T Ford; J C Gazet; C L Harmer; H White; C A Parsons; A Villardo; G Walsh; J A McKinna
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-28

8.  Oral high-dose medroxyprogesterone acetate versus tamoxifen. A randomized crossover trial in postmenopausal patients with advanced breast cancer.

Authors:  H van Veelen; P H Willemse; T Tjabbes; M J Schweitzer; D T Sleijfer
Journal:  Cancer       Date:  1986-07-01       Impact factor: 6.860

9.  Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).

Authors:  H B Muss; E H Paschold; W R Black; M R Cooper; R L Capizzi; R Christian; J M Cruz; D V Jackson; J J Stuart; F Richards
Journal:  Semin Oncol       Date:  1985-03       Impact factor: 4.929

10.  Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

Authors:  P A Canney; T J Priestman; T Griffiths; T N Latief; J J Mould; D Spooner
Journal:  J Natl Cancer Inst       Date:  1988-09-21       Impact factor: 13.506
View more
  8 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

3.  Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer.

Authors:  S Lundgren; P E Lønning; A Aakvaag; S Kvinnsland
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 5.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

6.  Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies.

Authors:  C M Camaggi; E Strocchi; A Martoni; C Zamagni; N Cacciari; G Robustelli della Cuna; L Pavesi; M Tedeschi; A Silva; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

Authors:  Lorna Gibson; David Lawrence; Claire Dawson; Judith Bliss
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

8.  Letrozole in advanced breast cancer: the PO25 trial.

Authors:  Henning T Mouridsen
Journal:  Breast Cancer Res Treat       Date:  2007-02-27       Impact factor: 4.872
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.